B-lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8+ T-cells

Scandinavian Journal of Immunology

Volumn 60, Issue 6, 2004, Pages 543-551

  Ritchie, D S ^a   Yang, J ^a   Hermans, I F ^a   Ronchese, F ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BINDING PROTEIN; CD40 LIGAND; EPITOPE; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; HISTOCOMPATIBILITY ANTIGENS CLASS II; LIPOPOLYSACCHARIDES; MICE; NEOPLASMS; SPLEEN;

EID: 10844251061     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01517.x     Document Type: Article

References (38)

1. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378:617-20.
2. Di Santo JP, de Saint Basile G, Durandy A, Fischer A. Hyper-IgM syndrome. Res Immunol 1994;145:205-9.
3. + T-helper and a T-killer cell. Nature 1998;393:474-8.
4. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-80.
5. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
6. Hermans IF, Ritchie DS, Daish A, Yang J, Kehry MR, Ronchese F. Impaired ability of MHC class II-/- dendritic cells to provide tumour protection is rescued by CD40 ligation. J Immunol 1999;163:77-81.
7. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922.
8. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14:591-617.
9. + T cells: role of TGF-β1. J Immunol 2003;170:5897-911.
10. Schultze JL, Cardoso AA, Freeman GJ et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumour immunogenicity. Proc Natl Acad Sci USA 1995;92:8200-4.
11. Van den Hove IE, Van Gool SW, Vandenberghe P et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997;11:572-80.
12. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997;159:5782-5.
13. Buhlmann JE, Foy TM, Aruffo A et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995;2:645-53.
14. Schultze JL. Vaccination as immunotherapy for B cell lymphoma. Hematol Oncol 1997;15:129-39.
15. Dilloo D, Brown M, Roskrow M et al. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997;90:1927-33.
16. Briones J, Timmerman J, Levy R. In vivo antitumour effect of CD40L-transduced tumour cells as a vaccine for B-cell lymphoma. Cancer Res 2002;62:3195-9.
17. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998;101:1133-41.
18. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989;342:559-61.
19. Hermans IF, Daish A, Moroni-Rawson P, Ronchese F. Tumour-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumour challenge. Cancer Immunol Immunother 1997;44:341-7.
20. Kehry MR, Castle BE. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin Immunol 1994;6:287-94.
21. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. New York; John Wiley & Sons, 2001:5.3.1-24.
22. Oehen S, Brduscha-Riem K. Correlation of effector function with phenotype and cell division. J Immunol 1998;161:5338-46.
23. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F. Antigen expressed on tumour cells fails to elicit an immune response, even in the presence of increased numbers of tumour-specific cytotoxic T lymphocyte precursors. Cancer Res 1998;58:3909-17.
24. Kemp R, Ronchese F. Tumour specific Tc1, but not Tc2, cells deliver protective anti-tumour immunity. J Immunol 2002;167:6497-502.
25. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992;175:131-8.
26. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992;258:1156-9.
27. + T cells. J Exp Med 1998;188:1977-83.
28. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1:362-7.
29. Regnault A, Lankar D, Lacabanne V et al. Peg receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalisation. J Exp Med 1999;189:371-80.
30. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM. Autologous tumour infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997;89:3806-16.
31. + dendritic cells in vivo. J Exp Med 2002;195:683-94.
32. Guo Y, Wu M, Chen H et al. Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994;263:518-20.
33. Ashwell JD. Are B lymphocytes the principal antigen-presenting cells in vivo? J Immunol 1988;140:3697-700.
34. Lassila O, Vainio O, Matzinger P. Can B cells turn on virgin T cells? Nature 1988;334:253-5.
35. Ronchese F, Hausmann B. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J Exp Med 1993;177:679-90.
36. Townsend SE, Goodnow CC. Abortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo. J Exp Med 1998;187:1611-21.
37. Morgan GM, Dellos H, McKenzie IF, Melvold RW, Bailey DW. Studies of two H-2Db mutants: B6.C-H-2bm13 and B6.C-H-2bm14. Immunogenetics 1980;11:341-9.
38. French RR, Chan HTC, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response rhat eradicares lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53.